Market Cap
$1.9B
VIR
Vir Biotechnology, Inc.
$11.02 ▼ -2.35%
Prev close $11.29Market cap$1.9B
12-mo target$20.78 (+88.5%)
Insider Selling Cluster (2 insiders)29 New Institutional Positions21 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on VIR right now — valuation, ownership and activity at a glance.
Cap Size
Small Cap
Inst. Holders
50 funds
Inst. Value
$949.7M
Inst. Activity
29 buys / 21 sells
Insider Activity
$0.00 buy / $2.4M sell
Insider Net $
-$2.4M
SEC Reports
18
Price chart 30d -4.1%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 2, 2026 clinical_trial_readout
T-90d Trial Readout: Tobevibart (Phase 3)
Trial: A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection Sponsor: Vir Biotechnolog
Sep 23, 2026 Event
Aug 18, 2026 SEC Smith v. Vir Biotechnology, Inc.
Court ruling (cand) — Docket: 3:25-cv-09682
A joint stipulation in Smith v. Vir Biotechnology, Inc. was approved by the court, extending the mediation deadline from
COURT-RULING — Impact 1/10
Aug 11, 2026 Insider
Aug 9, 2026 SEC MORE ROBERT J disposed of 8,000 shares
Director
Six institutional investors added a net $44.9M to Vir Biotechnology in Q2 2026, led by State Street (+$37.6M) and Pictet
INST-CLUSTER — Impact 5/10
Vir Biotechnology disclosed that CFO Jason O'Byrne will step down on August 3, 2026 to pursue another opportunity, with
8-K — Impact 3/10
Jun 30, 2026 Inst.
STATE STREET CORP — ADD
9,964,151 shares ($101.5M)
Jun 30, 2026 Inst.
Point72 Asset Management, L.P. — DOUBLED
5,666,821 shares ($57.7M)
Analyst ratings buy % +0.0%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Jun 11, 2026 | Morgan Stanley | MAINTAIN | Overweight | 55% |
| Jun 3, 2026 | Leerink Partners | MAINTAIN | Outperform | 49% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 4 | 9 | 1 | 0 | 0 | 93% | |
| Aug 1, 2026 | 4 | 9 | 1 | 0 | 0 | 93% | |
| Jul 1, 2026 | 4 | 9 | 1 | 0 | 0 | 93% | |
| Jun 1, 2026 | 4 | 9 | 1 | 0 | 0 | 93% | |
| May 1, 2026 | 4 | 9 | 1 | 0 | 0 | 93% | |
| Apr 1, 2026 | 4 | 9 | 1 | 0 | 0 | 93% | |
| Mar 1, 2026 | 3 | 10 | 1 | 0 | 0 | 93% | |
| Feb 1, 2026 | 3 | 10 | 1 | 0 | 0 | 93% |
Price targets
Where 9 covering analysts think VIR trades over the next 12 months.
$20.78 +88.5% upside Strong Buy
Current$11.03 Low$15.00 Median$20.00 High$30.00 9 analysts
$15.00$30.00
Analyst rating Strong Buy· 1.3/5 as of Oct 2, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
18 SEC filing reports analyzed · 1 bullish, 4 bearish, 0 mixed, 13 neutral · avg impact 3.4/10.
NEUTRALCOURT-RULING1/10
A joint stipulation in Smith v. Vir Biotechnology, Inc. was approved by the court, extending the med
Aug 18, 2026
BULLISHINST-CLUSTER5/10
Six institutional investors added a net $44.9M to Vir Biotechnology in Q2 2026, led by State Street
Aug 9, 2026
NEUTRAL8-K3/10
Vir Biotechnology disclosed that CFO Jason O'Byrne will step down on August 3, 2026 to pursue anothe
Jul 24, 2026
NEUTRAL1442/10
Former director Saira Ramasastry filed a Form 144 on June 29, 2026, indicating intent to sell 16,000
Jun 29, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Oct 2, 2026
Clinical Trial
A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection
Phase Phase 3 — ACTIVE_NOT_RECRUITING
Oct 2, 2026
clinical_trial_readout
T-90d Trial Readout: Tobevibart (Phase 3)
Trial: A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection Sponsor: Vir Biotechnology, Inc. Phase: Phase 3 | Status: ACTIVE_NOT_RECRUI
Sep 30, 2026
short_volume
Short Volume: VIR — 68.2% short (0.4M / 0.6M)
Short: 385,451 | Exempt: 1,014 | TRF Vol: 564,790 | Short Ratio: 68.2% | Off-exchange volume (dark pool + OTC)
Sep 24, 2026
short_volume
Short Volume: VIR — 67.2% short (0.4M / 0.6M)
Short: 434,749 | Exempt: 100 | TRF Vol: 646,810 | Short Ratio: 67.2% | Off-exchange volume (dark pool + OTC)
Sep 23, 2026
short_volume
Short Volume: VIR — 61.3% short (0.4M / 0.6M)
Short: 366,646 | Exempt: 0 | TRF Vol: 598,059 | Short Ratio: 61.3% | Off-exchange volume (dark pool + OTC)
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-0.73 | $-0.95–$-0.58 | 37.5% | +9.3% | 2↑ 2↓ | $0.0B | 7 |
| Next Q | $-0.63 | $-0.78–$-0.49 | -103.1% | -2.5% | 2↑ 2↓ | $0.0B | 7 |
| Current FY | $-1.76 | $-2.22–$-1.37 | 44.5% | +1.4% | 0↑ 4↓ | $0.2B | 7 |
| Next FY | $-2.49 | $-2.94–$-1.57 | -41.7% | +0.2% | 1↑ 2↓ | $0.1B | 7 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-0.732 | — |
| 7d ago | $-0.745 | +0.014 |
| 30d ago | $-0.806 | +0.075 |
| 60d ago | $-0.806 | +0.075 |
| 90d ago | $-0.806 | +0.075 |
Institutional ownership
Which big funds own VIR (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $949.7M total value (93,173,218 shares) as of 2026-Q2. Top holders: NOMURA, BlackRock,, VANGUARD. Net buying activity: 29 institutions added/increased vs 21 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| NOMURA ASSET MANAGEMENT CO LTD | 0 | $0.00 | 0.0% | — |
| BlackRock, Inc. | 20,678,283 | $210.7M | 22.2% | — |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 11,495,215 | $117.1M | 12.3% | — |
| STATE STREET CORP | 9,964,151 | $101.5M | 10.7% | ADD +39.5% |
| VANGUARD CAPITAL MANAGEMENT LLC | 6,388,775 | $65.1M | 6.9% | — |
| Point72 Asset Management, L.P. | 5,666,821 | $57.7M | 6.1% | DOUBLED +190.3% |
| GEODE CAPITAL MANAGEMENT, LLC | 3,348,366 | $34.1M | 3.6% | ADD +26.0% |
| DIMENSIONAL FUND ADVISORS LP | 3,119,421 | $31.8M | 3.3% | — |
| GOLDMAN SACHS GROUP INC | 2,365,219 | $24.1M | 2.5% | TRIM -27.2% |
| FMR LLC | 2,318,294 | $23.6M | 2.5% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| STATE STREET CORP | ADD | 7,141,094 | 9,964,151 | +39.5% | $101.5M |
| Point72 Asset Management, L.P. | DOUBLED | 1,952,234 | 5,666,821 | +190.3% | $57.7M |
| GEODE CAPITAL MANAGEMENT, LLC | ADD | 2,657,843 | 3,348,366 | +26.0% | $34.1M |
| GOLDMAN SACHS GROUP INC | TRIM | 3,250,227 | 2,365,219 | -27.2% | $24.1M |
| Nuveen, LLC | ADD | 1,018,964 | 1,982,942 | +94.6% | $20.2M |
| Pictet Asset Management Holding SA | ADD | 1,480,828 | 1,953,316 | +31.9% | $19.9M |
| NORTHERN TRUST CORP | ADD | 985,435 | 1,432,165 | +45.3% | $14.6M |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 761,364 | 1,016,864 | +33.6% | $10.4M |
| CITADEL ADVISORS LLC | TRIM | 2,098,476 | 991,337 | -52.8% | $10.1M |
| JPMORGAN CHASE & CO | TRIM | 1,117,516 | 802,597 | -28.2% | $8.3M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
13 insiders, 50 transactions. Net -$2.4M — $0.00 bought, $2.4M sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Aug 11, 2026 | MORE ROBERT J | Director | J | 8,000 | — | — |
| Jun 9, 2026 | Coughlin Timothy | Director | AWARD | 8,000 | — | — |
| Jun 9, 2026 | Coughlin Timothy | Director | AWARD | 16,000 | — | — |
| Jun 1, 2026 | Sabatini Brent | SVP, Chief Accounting Officer | SELL | 379 | $9.45 | $3.6K |
| Jun 1, 2026 | Napolitano Janet | Director | SELL | 3,200 | $9.45 | $30.2K |
| May 27, 2026 | Napolitano Janet | Director | AWARD | 8,000 | — | — |
| May 27, 2026 | BISCHOFBERGER NORBERT W | Director | AWARD | 8,000 | — | — |
| May 27, 2026 | BISCHOFBERGER NORBERT W | Director | AWARD | 16,000 | — | — |
| May 27, 2026 | Farid Ramy | Director | AWARD | 8,000 | — | — |
| May 27, 2026 | Farid Ramy | Director | AWARD | 16,000 | — | — |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for VIR.
Shares short
19,660,671
Settlement Sep 15, 2026
Change vs prior
-7.9%
Semi-monthly cycle
Days to cover
9.5
At avg daily volume
Of shares outstanding
≈11.6%
Estimate — not % of float
All VIR filing & press-release reports (18)
- COURT-RULING reportAug 18, 2026
- INST-CLUSTER reportAug 9, 2026
- 8-K reportJul 24, 2026
- 144 reportJun 29, 2026
- 3 reportJun 10, 2026
- 8-K reportJun 10, 2026
- CLUSTER reportJun 2, 2026
- 8-K reportMay 28, 2026
- DEFA14A reportApr 16, 2026
- 8-K reportApr 10, 2026
- CLUSTER reportApr 7, 2026
- 8-K reportMar 4, 2026
- CLUSTER reportMar 3, 2026
- CLUSTER reportFeb 26, 2026
- CLUSTER reportFeb 25, 2026
- CLUSTER reportFeb 25, 2026
- CLUSTER reportFeb 25, 2026
- CLUSTER reportFeb 25, 2026